All Professionals
Overview
Chris Guerin is an associate in the Securities and Capital Markets practice of Paul Hastings and is based in the firm's New York office. His practice includes representation of clients across the life sciences and technology industries, which include global investment banks as well as public and private companies. Mr. Guerin advises clients in a variety of capital markets transactions including IPOs, follow-on offerings, and private placements of equity and debt securities, as well as venture financings, mergers and acquisitions, securities law compliance and corporate governance.
Education
- Fordham University School of Law, J.D. (cum laude), 2018
- College of the Holy Cross, B.A., 2012
Representations
- J.P. Morgan Securities and other underwriters in the Initial Public Offering and subsequent PIPE financing by Lexeo Therapeutics, Inc., aggregating over $200 million
- Morgan Stanley, J.P. Morgan Securities, Rabo Securities and other underwriters in the $1.1 billion senior notes offering by AGCO Corporation
- TD Cowen and other underwriters in the $45 million follow-on offering by Humacyte, Inc.
- Jefferies in the $90 million follow-on offering by Esperion Therapeutics, Inc.
- Leerink Partners in the $80 million follow-on offering by PepGen Inc.
- Piper Sandler and the other placement agents in PIPE financings by Skye Biosciences, Inc., aggregating over $90 million
- Wells Fargo, BofA Securities, J.P. Morgan Securities and other underwriters in the $600 million green bond offering by American Homes 4 Rent
- Goldman Sachs & Co. LLC and the other underwriters in the $215 million follow-on offering by Syndax Pharmaceuticals, Inc.
- BofA Securities and Goldman Sachs & Co. LLC in the $350 million private placement by Arvinas, Inc.
- Jefferies and Leerink Partners in the $50 million follow-on offering by AC Immune SA
- Disc Medicine, Inc. in its reverse merger and follow on offerings aggregating over $290 million in proceeds
- HOOKIPA Pharma Inc. in its follow-on offerings aggregating over $120 million in proceeds
- Goldman Sachs & Co. LLC in the follow-on offering by Taysha Gene Therapies
- Goldman Sachs & Co. LLC and other underwriters in the $140 million follow-on offering by Syndax Pharmaceuticals, Inc.
- Goldman Sachs & Co. LLC and other underwriters in the $102 million follow-on offering by Valneva SE
- Goldman Sachs & Co. LLC and the other initial purchasers in the $460 million convertible notes offering by 3D Systems Corporation
- Goldman Sachs & Co. LLC and the other initial purchasers in the $230 million convertible notes offering by Cutera, Inc.
- J.P. Morgan Securities and other underwriters in the $75 million follow-on offering by Precigen, Inc.
- J.P. Morgan Securities and the other initial purchasers in the $115 million convertible notes offering by Desktop Metal, Inc.
Matters may have been completed before joining Paul Hastings